Ottimo Pharma is developing Jankistomig, a PD1-VEGFR2 bi-functional antibody that targets immune checkpoint inhibition and angiogenesis in a single IgG therapy. This approach aims to improve treatment outcomes for cancer patients while reducing the overall healthcare burden associated with cancer therapies.
Funding
$140M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often address either immune checkpoint inhibition or angiogenesis, requiring multiple treatments and potentially increasing the healthcare burden for patients. This fragmented approach may not fully address the complex mechanisms driving cancer progression.
Solution
Ottimo Pharma is developing Jankistomig, a bi-functional antibody that simultaneously targets PD1 for immune checkpoint inhibition and VEGFR2 for angiogenesis. This single IgG therapy aims to provide a more comprehensive approach to cancer treatment by addressing two critical pathways involved in tumor growth and spread. By combining these mechanisms into one therapeutic, Ottimo Pharma seeks to improve patient outcomes and reduce the overall complexity and cost associated with cancer care. The therapy is planned to enter clinical trials in 2025.
Target Audience
The primary target audience includes cancer patients who could benefit from a more comprehensive treatment approach, as well as oncologists and healthcare providers seeking to improve patient outcomes and reduce the complexity of cancer therapy regimens.
Features
- Bi-functional antibody targeting both PD1 and VEGFR2
- Single IgG therapy designed for dual-pathway inhibition
- Aims to improve cancer treatment outcomes compared to single-target therapies
- Designed to reduce the healthcare burden associated with cancer therapies